Benitec Biopharma
BNTC
19 hedge funds and large institutions have $44.3M invested in Benitec Biopharma in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 1 closing their positions.
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
574% more capital invested
Capital invested by funds: $6.58M → $44.3M (+$37.7M)
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
46% more funds holding
Funds holding: 13 → 19 (+6)
18.75% more ownership
Funds ownership: 49.07% → 67.82% (+19%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$11M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$6.21M |
| 3 |
Janus Henderson Group
London,
|
+$4.84M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.81M |
| 5 |
AIC
AWM Investment Company
New York
|
+$4.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$45.7K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6.3K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$89 |
BNTC Hedge Fund Activity: Q2 2024 in Review
19 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q2 2024, worth a combined $44.3M — up 574% from $6.58M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BNTC positions and 1 closed out — a net gain of 6 holders — while 8 added to existing stakes and 2 trimmed.
The largest buyer was Suvretta Capital Management, adding an estimated $11M. The largest seller was Morgan Stanley, cutting an estimated $45.7K.
- 19 institutional investors held Benitec Biopharma (BNTC) as of Q2 2024, up from 13 in Q1 2024.
- Funds reported $44.3M of Benitec Biopharma stock for Q2 2024, up 574% quarter-over-quarter.
- 7 funds opened new Benitec Biopharma positions in Q2 2024 and 1 closed out, a net change of +6 holders.
- The largest Benitec Biopharma buyer in Q2 2024 was Suvretta Capital Management, an estimated $11M added.
- The largest Benitec Biopharma seller in Q2 2024 was Morgan Stanley, an estimated $45.7K sold.
Based on aggregated 13F filings for Q2 2024.